Insider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $246,109.17 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 12,563 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $19.59, for a total value of $246,109.17. Following the completion of the sale, the chief executive officer now owns 3,775,772 shares of the company’s stock, valued at $73,967,373.48. This represents a 0.33 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Christopher Richard Anzalone also recently made the following trade(s):

• On Wednesday, December 18th, Christopher Richard Anzalone sold 26,712 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $21.24, for a total value of $567,362.88.

Arrowhead Pharmaceuticals Trading Down 0.6 %

ARWR stock opened at $19.63 on Thursday. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $17.05 and a twelve month high of $39.83. The company has a market cap of $2.44 billion, a P/E ratio of -3.91 and a beta of 0.91. The business has a fifty day moving average of $21.23 and a 200-day moving average of $22.93.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fifth Third Bancorp grew its position in shares of Arrowhead Pharmaceuticals by 42.5% during the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after buying an additional 354 shares during the period. Bank of New York Mellon Corp boosted its stake in Arrowhead Pharmaceuticals by 2.9% in the second quarter. Bank of New York Mellon Corp now owns 1,085,069 shares of the biotechnology company’s stock valued at $28,201,000 after acquiring an additional 30,086 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Arrowhead Pharmaceuticals by 20.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,739 shares of the biotechnology company’s stock worth $747,000 after acquiring an additional 4,927 shares during the period. Commonwealth Equity Services LLC raised its position in shares of Arrowhead Pharmaceuticals by 3.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 34,663 shares of the biotechnology company’s stock valued at $901,000 after acquiring an additional 1,250 shares during the last quarter. Finally, nVerses Capital LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $96,000. 62.61% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ARWR has been the subject of a number of recent research reports. Piper Sandler dropped their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Citigroup decreased their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, November 27th. Chardan Capital restated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $42.70.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.